疑/尚无定论 - 有抗体的新冠肺炎治愈者不会再感染，可以发免疫护照

流传说法：展开

较真鉴定：疑尚无定论

查证要点：

现阶段尚无足够证据证明抗体介导免疫的有效性，不能保证新型冠状肺炎治愈者不会再次感染，因此也无法保证“免疫护照”的准确性。
通过自然感染对病毒产生免疫需要经过多个步骤，人体从而产生联合适应性免疫应答清除毒素，如果应答足够强就可防止同一病毒再次感染。这通过血液中抗体的存在来衡量。
目前大多数研究表明，康复的感染者拥有对该病毒的抗体。但截至2020年4月24日，尚无研究评估SARS-CoV-2抗体能否使人类免疫后续感染。
对人体内SARS-CoV-2抗体的实验室检测，其准确性和可靠性仍需要进一步验证。免疫诊断检测如果不准确，可能会导致：第一，将已感染者标记为阴性，第二，将未感染者标记为阳性。

查证者：世界卫生组织联合国系统内卫生问题的指导和协调机构

参考文献

ConsiderationsinadjustingpublichealthandsocialmeasuresinthecontextofCOVID-19.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/critical-preparedness-readiness-andresponse-actions-for-covid-19
WölfelR,CormanVM,GuggemosW,etal.VirologicalassessmentofhospitalizedpatientswithCOVID-2019.Nature2020.
ToKK,TsangOT,LeungWS,etal.TemporalprofilesofviralloadinposteriororopharyngealsalivasamplesandserumantibodyresponsesduringinfectionbySARS-CoV-2:anobservationalcohortstudy.LancetInfectDis.2020Mar23.pii:S1473-3099(20)30196-1.doi:10.1016/S1473-3099(20)30196-1.
WuF,WangA,LiuM,etal.NeutralizingantibodyresponsestoSARS-CoV-2inaCOVID-19recoveredpatientcohortandtheirimplications.medRxiv2020:2020.03.30.20047365.
JuB,ZhangQ,GeX,etal.PotenthumanneutralizingantibodieselicitedbySARS-CoV-2infection.Biorxiv2020:2020.03.21.990770.
PohCM,CarissimoG,WangB,etal.PotentneutralizingantibodiesintheseraofconvalescentCOVID-19patientsaredirectedagainstconservedlinearepitopesontheSARS-CoV-2spikeprotein.Biorxiv2020:2020.03.30.015461.
ZhangW,DuR,LiB,ZhengX,etal.Molecularandserologicalinvestigationof2019-nCoVinfectedpatients:implicationofmultiplesheddingroutes.EmergMicrobesInfect.2020Feb17;9(1):386-389.doi:10.1080/22221751.2020.1729071.
GrzelakL,TemmamL,PlanchaisC,etal.SARS-CoV-2serologicalanalysisofCOVID-19hospitalizedpatients,paucisymptomaticindividualsandblooddonors.medRxiv2020(submitted17April2020).
AmanatF,NguyenT,ChromikovaV,etal.AserologicalassaytodetectSARS-CoV-2seroconversioninhumans.medRxiv2020:2020.03.17.20037713.
OkbaNMA,MüllerMA,LiW,etal.Severeacuterespiratorysyndromecoronavirus2−specificantibodyresponsesincoronavirusdisease2019patients.EmergInfectDis.2020doi:10.3201/eid2607.200841
ZhaoJ,YuanQ,WangH,etal.AntibodyresponsestoSARS-CoV-2inpatientsofnovelcoronavirusdisease2019.ClinInfectDis.2020doi:10.1093/cid/ciaa344
GuoL,RenL,YangS,etal.ProfilingEarlyHumoralResponsetoDiagnoseNovelCoronavirusDisease(COVID-19).ClinInfectDis.2020Mar21.doi:10.1093/cid/ciaa310.
LiuY,LiuY,DiaoB,RenFeifei,etal.DiagnosticindexesofarapidIgG/IgMcombinedantibodytestforSARS-CoV-2.medRxiv2020;doi:10.1101/2020.03.26.20044883
ZhangP,GaoQ,WangT,KeY,etal.Evaluationofrecombinantnucleocapsidandspieproteinserologicaldiagnosisofnovelcoronavirusdisease2019(COVID-19).medRxiv.2020;doi:10.1101/2020.03.17.20036954
PanY,LiX,YangG,FanJ,etal.SerologicalimmunochromatographicapproachindiagnosiswithSARS-CoV-2infectedCOVID-19patients.medRxiv.2020;doi:10.1101/2020.03.13.20035428
LiZ,YiY,LuoX,XionN,etal.DevelopmentandclinicalapplicationofarapidIgM-IgGcombinedantibodytestforSARSCoV-2infectiondiagnosis.JMedVirol.2020Feb27.doi:10.1002/jmv.25727.
LiR,PeiS,ChenB,etal.Substantialundocumentedinfectionfacilitatestherapiddisseminationofnovelcoronavirus(SARSCoV2).Science2020.
LouB,LiT,ZhengS,SuY,LiZ,LiuW,etal.SerologycharacteristicsofSARS-CoV-2infectionsincetheexposureandpostsymptomsonset.medRxiv2020;doi:10.1101/2020.03.23.20041707
LinD,LiuL,ZhangM,HuY,etal.Evaluationofserologicaltestsinthediagnosisof2019novelcoronavirus(SARS-CoV-2)infectionsduringtheCOVID-19outbreak.medRxiv2020.doi:10.1101/2020.03.27.20045153
LiuW,LiuL,KouG,ZhengY,etal.Evaluationofnucleocapsidandspikeprotein-basedELISAsfordetectingantibodiesagainstSARS-CoV-2.medxriv[Internet].2020;Availablefrom:https://doi.org/10.1101/2020.03.16.20035014medRxivpreprint
UnityStudies:EarlyInvestigationProtocolshttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/early-investigations